Latest Insider Transactions at Intellia Therapeutics, Inc. (NTLA)
This section provides a real-time view of insider transactions for Intellia Therapeutics, Inc. (NTLA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Intellia Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Intellia Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 14
2022
|
John F Crowley Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+41.62%
|
-
|
|
Jun 14
2022
|
Caroline Dorsa Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+29.04%
|
-
|
|
Jun 14
2022
|
Jean Francois Formela Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+41.62%
|
-
|
|
Jun 14
2022
|
Jesse Goodman |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+41.62%
|
-
|
|
Jun 14
2022
|
Georgia Keresty |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+30.72%
|
-
|
|
Jun 14
2022
|
Frank Verwiel |
BUY
Grant, award, or other acquisition
|
Direct |
5,197
+41.62%
|
-
|
|
Apr 28
2022
|
Muna Bhanji |
BUY
Grant, award, or other acquisition
|
Direct |
7,954
+50.0%
|
-
|
|
Mar 01
2022
|
Eliana Clark EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,527
+39.44%
|
-
|
|
Mar 01
2022
|
John M Leonard President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
40,990
+5.08%
|
-
|
|
Mar 01
2022
|
James Basta EVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
20,697
+40.9%
|
-
|
|
Mar 01
2022
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,720
+46.27%
|
-
|
|
Mar 01
2022
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,816
+35.84%
|
-
|
|
Mar 01
2022
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
13,816
+42.58%
|
-
|
|
Jan 03
2022
|
Derek Hicks EVP, Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,118
+50.0%
|
-
|
|
Jan 01
2022
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
2,493
-0.34%
|
$279,216
$112.25 P/Share
|
|
Jan 01
2022
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
7,848
+1.07%
|
-
|
|
Jan 01
2022
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,013
-33.08%
|
$113,456
$112.24 P/Share
|
|
Jan 01
2022
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,062
+50.0%
|
-
|
|
Jan 01
2022
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
1,051
-8.78%
|
$117,712
$112.24 P/Share
|
|
Jan 01
2022
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,187
+21.02%
|
-
|
|
Jan 01
2022
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,148
-19.25%
|
$128,576
$112.25 P/Share
|
|
Jan 01
2022
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+36.99%
|
-
|
|
Nov 05
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-5.85%
|
$319,200
$133.44 P/Share
|
|
Nov 05
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+17.76%
|
$28,800
$12.62 P/Share
|
|
Oct 14
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-4.73%
|
$307,200
$128.81 P/Share
|
|
Oct 14
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+17.76%
|
$28,800
$12.62 P/Share
|
|
Oct 11
2021
|
John F Crowley Director |
SELL
Open market or private sale
|
Direct |
2,500
-54.42%
|
$297,500
$119.55 P/Share
|
|
Oct 11
2021
|
John F Crowley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+35.24%
|
$45,000
$18.83 P/Share
|
|
Oct 05
2021
|
John F Crowley Director |
SELL
Open market or private sale
|
Direct |
10,000
-27.69%
|
$1,300,000
$130.84 P/Share
|
|
Oct 05
2021
|
John F Crowley Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+45.26%
|
$180,000
$18.83 P/Share
|
|
Sep 24
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,923
+47.62%
|
$95,076
$12.62 P/Share
|
|
Sep 21
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-75.21%
|
$357,600
$149.81 P/Share
|
|
Sep 21
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+42.93%
|
$28,800
$12.62 P/Share
|
|
Sep 07
2021
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,482
-100.0%
|
$626,760
$180.12 P/Share
|
|
Sep 07
2021
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,482
+50.0%
|
$48,748
$14.58 P/Share
|
|
Sep 01
2021
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
44,735
-5.86%
|
$7,604,950
$170.0 P/Share
|
|
Sep 01
2021
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
44,735
+2.88%
|
$894,700
$20.88 P/Share
|
|
Aug 31
2021
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
24,800
-100.0%
|
$3,968,000
$160.22 P/Share
|
|
Aug 31
2021
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,800
+28.41%
|
$396,800
$16.93 P/Share
|
|
Aug 31
2021
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
37,833
-5.0%
|
$5,864,115
$155.0 P/Share
|
|
Aug 31
2021
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,833
+4.76%
|
$529,662
$14.58 P/Share
|
|
Aug 30
2021
|
Glenn Goddard EVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,200
-40.58%
|
$811,200
$156.88 P/Share
|
|
Aug 30
2021
|
Glenn Goddard EVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,200
+50.0%
|
$98,800
$19.27 P/Share
|
|
Aug 30
2021
|
David Lebwohl EVP, Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,400
-22.08%
|
$376,800
$157.8 P/Share
|
|
Aug 30
2021
|
David Lebwohl EVP, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,400
+42.93%
|
$28,800
$12.62 P/Share
|
|
Aug 30
2021
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
97,000
-32.43%
|
$15,132,000
$156.7 P/Share
|
|
Aug 30
2021
|
Laura Sepp Lorenzino EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
97,000
+44.6%
|
$1,261,000
$13.83 P/Share
|
|
Aug 30
2021
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
38,804
-0.58%
|
$6,053,424
$156.86 P/Share
|
|
Aug 30
2021
|
John M Leonard President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
38,804
+2.51%
|
$504,452
$13.99 P/Share
|
|
Aug 23
2021
|
John M Leonard President and CEO |
SELL
Open market or private sale
|
Direct |
27,139
-1.22%
|
$4,125,128
$152.71 P/Share
|